Ekso Bionics (NASDAQ:EKSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report released on Sunday. The brokerage issued a hold rating on the stock.

A number of other research analysts have also issued reports on EKSO. HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Ekso Bionics in a research note on Tuesday, January 14th. Lake Street Capital decreased their target price on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th.

Ekso Bionics Trading Down 3.5 %

Shares of Ekso Bionics stock opened at $0.51 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. Ekso Bionics has a 1 year low of $0.47 and a 1 year high of $2.16. The business has a 50 day moving average price of $0.62 and a 200 day moving average price of $0.84. The company has a market capitalization of $11.31 million, a P/E ratio of -0.79 and a beta of 1.46.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.